Sciformix Opens New Office in Manila
News Aug 12, 2013
Sciformix Corporation has announced the opening of their new offices located in Manila, the Philippines. The expansion into Manila comes as part of Sciformix‘s continued growth and provides the opportunity for the company to utilize the region’s extensive resource of talented medical professionals.
Philippine Labor and Employment Secretary, Rosalinda Baldoz, welcomed the move by Sciformix and the opportunity for medical professionals to remain in the Philippines with attractive salaries and career opportunities.
“Sciformix’s continued growth and success has created an opportunity for our expansion into Manila, which is an important piece of our strategy and global footprint. As a leading SPO, this move takes us forward with the goal of adding more than 200 highly skilled employees in the Philippines”, said Manish Vinayak Soman, Sciformix President and Chief Executive Officer (CEO).
Sciformix, recent winner of Frost & Sullivan’s Pharmaceutical Knowledge Process Outsourcing (KPO) Entrepreneurial Company of the Year award, has experienced remarkable growth to become an SPO, a sub-category of KPO specializing in life sciences.
The company’s investment in its people and technologies has enabled the business to deliver its clients differentiated services, resulting in rapid double digit revenue growth.
Sciformix has a unique positioning as a SPO, in that it combines deep expertise in workflow processes optimization with scientific knowledge, which delivers in line with their cost efficiency model.
This expansion into the Philippines also sees Sciformix as the first company based in Manila to undertake case management activities. A 135-strong team from Sciformix’s Philippines and India centers is supporting one of its Fortune 100 company clients that specializes in consumer healthcare, medical devices and diagnostics, and pharmaceuticals.
Sciformix, headquartered in the USA, with operations in India and the Philippines, partners with life science organizations through the entire drug development cycle to provide a full range of services from study design to post marketing surveillance and commercialization support.
Areas of specialization include Safety and Risk Management, Clinical Research & Post Approval Services, Medical Affairs, Scientific Writing and Regulatory Affairs.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018